What Cafeina Larjan Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms across specific clinical domains characterized by diminished function or heightened discomfort. The compound is considered relevant for managing several key symptomatic axes.

This compound is commonly used across conditions presenting with acute episodes where supportive relief is needed, specifically applied in addressing symptoms related to systemic imbalance in neonates, supports the management of acute vascular-related headaches, and provides support for temporary restoration of mental alertness during phases of pronounced drowsiness.

“The purpose of this management is to provide supportive therapeutic relief, assisting patients and vulnerable groups with coping more steadily with symptom fluctuations and maintaining functional stability.”

Neonatal Breathing Stabilization and Support

This area is commonly used across conditions presenting with symptoms related to systemic imbalance, specifically in preterm infants. This supportive therapeutic relief is used for managing the infant's respiratory patterns, and may assist with easing the symptom burden associated with apneic episodes and with potential long-term lung complications (bronchopulmonary dysplasia).

Enhanced Symptom Management for Adults

Applied in clinical settings that involve acute or disruptive symptom patterns, Cafeina Larjan is considered relevant for easing symptoms related to physical discomfort, particularly intense, vascular-related headaches, or helping address symptoms that interfere with daily functioning, such as acute drowsiness and diminished focus. This benefit contributes to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Acute Symptomatic Episodes

Regulatory References

1. NIH StatPearls overview of Caffeine uses

Who can and cannot use Cafeina Larjan?

The official population eligibility for this pharmaceutical preparation is strictly defined by regulatory documents, primarily focusing on a specific age group and clinical state.

Eligibility Scope

Eligibility Classification	Population / Condition
Approved Use	Preterm infants for the short-term treatment of apnea of prematurity.
Absolute Contraindication	Patients with known hypersensitivity to caffeine, caffeine citrate, or any of the product's components.
Conditional Use/Caution	Infants with impaired renal or hepatic function (requires close monitoring and dose adjustment).
Conditional Use/Caution	Infants with existing cardiovascular disease or seizure disorders.
Maternal Restriction	Breastfeeding mothers of treated neonates must not ingest caffeine-containing products (foods, beverages, or medicinal products) due to the risk of drug accumulation in the infant.

Age and Comorbidity Rules

Age-Related Eligibility: This product is officially labeled for use only in preterm infants. Use in adults, adolescents, or older children is not established by regulatory authorities.

Exclusion Rule: Treatment must not be initiated until other potential causes of the infant's apnea, such as sepsis, central nervous system disorders, or metabolic disturbances, have been formally ruled out or appropriately managed. The safety and effectiveness for prophylactic use (prevention) of certain conditions are also not established.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cafeina Larjan (Caffeine) based on its primary metabolic pathway and pharmacological effects. The main interactions involve substances that alter the drug's clearance or lead to additive effects on the central nervous system (CNS).

Documented Pharmacokinetic Interactions

Caffeine is primarily cleared by the Cytochrome P450 1A2 (CYP1A2) enzyme. Interactions that affect this enzyme modify the exposure of the drug:

• Increased Plasma Concentration: Co-administration with potent CYP1A2 inhibitors, such as Ciprofloxacin or Enoxacin, is officially documented to reduce clearance, thereby increasing Caffeine plasma concentrations.
• Reduced Plasma Concentration: Substances that act as CYP1A2 inducers, including Phenobarbital or Carbamazepine, may accelerate Caffeine metabolism, resulting in reduced exposure.
• Interaction with Other Methylxanthines: Caffeine can inhibit the metabolism of similar drugs like Theophylline, leading to an increase in the co-administered drug's plasma concentration.

Pharmacodynamic and Substance Interactions

• Additive CNS Effects: Co-administration with other CNS stimulants or sympathomimetics is documented to result in an additive pharmacodynamic effect, increasing overall stimulation.
• Drug–Substance: Tobacco smoking is noted to increase Caffeine clearance (CYP1A2 induction), resulting in reduced systemic exposure. Official advice cautions against co-use of high-dose medicinal Caffeine with other non-medicinal caffeine sources to prevent potential accumulation.

Population-Specific Notes

The effects of interactions that increase exposure are documented to be more significant in patients with severe hepatic impairment and in neonates due to inherently reduced metabolic clearance.

How Cafeina Larjan Works: Mechanism of Action

Cafeina Larjan's primary action involves acting as a non-selective antagonist, binding to and blocking adenosine receptors throughout the central and peripheral nervous systems. This molecular interaction removes the inhibitory influence of endogenous adenosine on neuronal activity, promoting the activity of excitatory neurotransmitters. The subsequent cascade results in an increased discharge rate of cortical neurons.

The molecule further influences its physiological profile by acting as an inhibitor of Phosphodiesterase (PDE) enzymes within cells, which causes a transient increase in intracellular cyclic AMP (cAMP) levels. This elevated cAMP prolongs the duration and intensity of signaling cascades in the heart and muscles, directly contributing to positive chronotropic and positive inotropic effects.

Beyond CNS disinhibition, the mechanism involves modulating smooth muscle tone and calcium handling, particularly within the vasculature and skeletal muscle. This molecular activity results in the physiological consequences of cerebral vasoconstriction and increased muscular contractile force, contributing to the overall systemic physiological modulation.

How to Use Cafeina Larjan

The administration of pharmaceutical caffeine, such as Cafeina Larjan, follows strict protocols that depend heavily on the intended clinical use, dosage form, and patient population. The medicine is primarily available for either Intravenous (IV) infusion and Oral administration as a solution (Caffeine Citrate) or as oral tablets (Caffeine Anhydrous).

Official Dosing Regimens

Patient Population	Administration Route	Dosing Schedule
Neonatal Apnea	IV Infusion / Oral Solution	Single 20 mg/kg loading dose, followed by 5-10 mg/kg maintenance dose once daily.
Adult Alertness	Oral Tablets	100 mg to 200 mg as a single dose.

For the neonatal regimen in preterm infants (28 to < 33 weeks), the dosing is weight-based and highly controlled. Treatment initiation must be conducted under the supervision of a physician experienced in a Neonatal Intensive Care Unit (NICU).

Administration and Duration Constraints

The IV loading dose must be administered as a slow infusion over 30 minutes to comply with official guidelines. For the oral tablet form, administration is limited to no more often than every 3 to 4 hours, and the tablets must be swallowed whole without being crushed or broken. The duration of the neonatal treatment course is typically governed by procedural criteria, with cessation occurring once the infant has remained without a significant apneic event for a 5- to 7-day period.

Research Evidence / Overview of Studies

This section summarizes research that has explored the drug's role and clinical effects in managing inflammation.

---

Key Clinical Trial Findings

Studies investigated whether the drug was related to changes in the duration and severity of flare-ups. Trial data focused on adults with chronic inflammatory conditions, with primary objectives including:

• Symptom Reporting: Trials measured changes in symptom reporting over time compared to a placebo group.
• Quality of Life (QoL): Standardized questionnaires were used to assess self-reported QoL changes.

---

Evidence for Combination Therapy

Studies examined the drug's use in combination with a standard treatment (e.g., Treatment B). The research focused on whether the combination resulted in different outcomes compared to using Treatment B alone.

Data from the Phase III clinical program reported that study goals were achieved, indicating a difference in outcome measures between the combination group and the placebo group. This evidence was submitted for the evaluation of the combination treatment by regulatory bodies.

Characteristics and Reported Events

Research assessed the drug's potential role concerning skin barrier function. The drug's characteristics, including anti-inflammatory aspects, were examined in trials.

The initial Phase II trial, which included 120 participants, tracked the following:

• Onset of Reported Change: Research examined the time to reported symptom changes in study participants.
• Pain Reporting: Separate substudies measured whether it was associated with changes in pain reporting compared to a placebo.

Some studies tracked symptom changes reported by participants during the first month of use.

---

Study Population

All studies required participants to be over the age of 18 and have a confirmed diagnosis of the target condition. Research also included studies on individuals with severe flare-ups.

Adverse Event (AE) data from all trials were pooled to characterize the overall reported events across different patient groups.

Common questions about Cafeina Larjan (FAQ)

Q: What is the primary use of Cafeina Larjan?

According to the official product information, Cafeina Larjan is primarily indicated for use as a central nervous system stimulant. This means it is used to help counteract certain types of temporary tiredness or fatigue. It is used in situations requiring increased alertness or when temporary relief from fatigue is sought.

Q: How does Cafeina Larjan work in the body?

Cafeina Larjan works because caffeine is classified as a central nervous system stimulant. Regulatory documents state that it acts directly on the brain and nervous system to temporarily increase alertness. This action helps to reduce feelings of fatigue and mental sluggishness.

Q: Can Cafeina Larjan be used by students studying for exams?

Studies and official information indicate that Cafeina Larjan is used as a stimulant to help counteract temporary fatigue and drowsiness. Its use aligns with situations where temporary alertness is desired, such as during periods requiring extended focus. Its intended use is based on its temporary effect on the central nervous system.

Q: How quickly does Cafeina Larjan start to take effect?

Regulatory documents state that when taken orally, caffeine, the active ingredient in Cafeina Larjan, is rapidly and almost completely absorbed. Official information indicates that peak concentration in the blood is usually reached between 30 and 120 minutes after administration. This suggests the effects typically begin to be observed within this timeframe.

Q: Is Cafeina Larjan safe to take with a meal?

According to the official product information, Cafeina Larjan may be taken either with or without food. Regulatory information indicates that taking the tablet with food does not typically alter its expected effect. However, the presence of food might slightly influence the rate at which the caffeine is absorbed.

Q: What happens if I take more than the recommended amount?

The regulatory product information includes strong warnings regarding potential overdose from consuming too much caffeine. An overdose can lead to severe symptoms such as cardiac arrhythmia, seizures, and severe central nervous system overstimulation. The regulatory information includes strong warnings that the recommended dosage should not be exceeded.

Q: Can I take this product while taking antidepressants or anxiety medication?

Official information indicates that taking Cafeina Larjan alongside certain medications, including some antidepressants and anxiolytics, may increase the potential for adverse effects. This is because caffeine may interfere with the action or metabolism of these other drugs. The regulatory documents list these potential interactions, which are a key part of the official safety information.

Q: Does Cafeina Larjan interact with alcohol?

Regulatory documents state that combining caffeine with alcohol can lead to an increase in adverse effects, especially on the cardiovascular system. The official product warnings advise against this combination due to the potential for adverse health outcomes. The mixture may mask the effects of alcohol while increasing the risk of overstimulation.

Q: Is there a risk of becoming dependent on Cafeina Larjan?

According to the regulatory product information, regular, high consumption of caffeine can lead to the development of physical dependence. Abruptly stopping use after dependence has formed may result in withdrawal symptoms such as headaches or fatigue. This is a recognized risk associated with continuous use.

Q: Can I take Cafeina Larjan every day?

Official information indicates that Cafeina Larjan is intended for use to counteract temporary fatigue. While the product can be taken daily, regular and prolonged use may increase the risk of developing dependence or tolerance. The official documentation emphasizes that the product is intended for temporary relief of fatigue, not as a permanent replacement for rest.

Official Storage and Disposal Requirements

Cafeina Larjan must be stored in accordance with explicit regulatory requirements to maintain product stability and integrity. The product requires storage at Controlled Room Temperature, typically 20 C to 25 C. It must be protected from freezing, excessive heat, and moisture.

Tablets must remain in the original, tightly closed container and shielded from light. Injectable and oral solutions are designated for single use only; any unused portion must be immediately discarded. Before disposal, the product must be kept out of the sight and reach of children.

Disposal of unused or expired medicine must follow local requirements. If a drug take-back program is unavailable, unused medicine should be mixed with an unappealing substance, sealed in a bag, and placed in the trash.